Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Selumetinib, a selective MEK1/2 inhibitor, achieved objective responses in 15% of patients with recurrent low-grade serous ovarian cancer. The data are relevant as this uncommon tumor type is associated with general chemoresistance, frequent aberration in the MAPK pathway, and prolonged overall survival compared with its more common high-grade variant. Phase 3 trials are planned.

Targeted Therapy for Low-grade Serous Ovarian Cancer Shows Promise